BCYC · Bicycle Therapeutics PLC · Documents
Market Cap
$253.74M
Shares
70.09M
Volume · Nov 3
81.49K
Avg daily vol (3M)
409.69K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 10-Q | Bicycle Therapeutics PLC prioritized nuzefatide pevedotin and next-generation conjugates in March 2026, cutting approximately 30% of its workforce and expecting annual operating expenses to fall approximately 50%. It reported a nine-month net loss of $121.6 million. | 2026-10-29 | 2026-09-30 | |
| 8-K | Bicycle Therapeutics plc received FDA Orphan Drug Designation for nuzefatide pevedotin in pancreatic cancer; BT1702 trial initiation is expected in the second half of 2027. Cash was $469.9 million as of September 30, 2026, and net loss was $10.5 million. | 2026-10-29 | — | |
| 8-K | — | 2026-08-20 | 2026-08-18 | |
| 10-Q | — | 2026-07-30 | 2026-06-30 | |
| 8-K | — | 2026-07-30 | — | |
| 8-K | — | 2026-06-18 | 2026-06-17 | |
| 8-K | — | 2026-05-21 | — | |
| 8-K | — | 2026-04-30 | — | |
| 10-Q | — | 2026-04-30 | 2026-03-31 | |
| ARS | — | 2026-04-22 | 2025-12-31 | |
| DEF 14A | — | 2026-04-22 | 2026-06-17 | |
| 8-K | — | 2026-04-20 | — | |
| PRE 14A | — | 2026-04-03 | 2026-06-17 | |
| 8-K | — | 2026-03-17 | — | |
| 10-K | — | 2026-03-17 | 2025-12-31 | |
| 8-K | — | 2026-02-03 | 2026-01-29 | |
| 8-K | — | 2026-01-12 | — | |
| 10-Q | — | 2025-10-30 | 2025-09-30 | |
| 8-K | — | 2025-10-30 | — | |
| 8-K | — | 2025-09-08 | — | |
| 10-Q | — | 2025-08-08 | 2025-06-30 | |
| 8-K | — | 2025-08-08 | 2025-08-06 | |
| S-3 | — | 2025-08-08 | — | |
| 8-K | — | 2025-06-17 | — | |
| 10-Q | — | 2025-05-01 | 2025-03-31 | |
| 8-K | — | 2025-05-01 | — | |
| 8-K | — | 2025-04-29 | — | |
| ARS | — | 2025-04-23 | 2024-12-31 | |
| DEF 14A | — | 2025-04-23 | 2025-06-17 | |
| PRE 14A | — | 2025-04-04 | 2025-06-17 | |
| 8-K | — | 2025-03-27 | 2025-03-21 | |
| 8-K | — | 2025-03-14 | 2025-03-12 | |
| 10-K | — | 2025-02-25 | 2024-12-31 | |
| 8-K | — | 2025-02-25 | — | |
| 8-K | — | 2025-01-13 | — | |
| 8-K | — | 2024-12-13 | — | |
| 10-Q | — | 2024-10-31 | 2024-09-30 | |
| 8-K | — | 2024-10-31 | — | |
| 8-K | — | 2024-10-23 | — | |
| 8-K | — | 2024-09-19 | 2024-09-14 | |
| 10-Q | — | 2024-08-06 | 2024-06-30 | |
| 8-K | — | 2024-08-06 | — | |
| 8-K | — | 2024-07-10 | 2024-07-09 | |
| 8-K | — | 2024-06-18 | — | |
| 8-K | — | 2024-05-23 | — | |
| 8-K | — | 2024-05-16 | — | |
| 8-K | — | 2024-05-02 | — | |
| 10-Q | — | 2024-05-02 | 2024-03-31 | |
| DEFA14A | — | 2024-04-18 | — | |
| 8-K | — | 2024-04-18 | 2024-04-16 |
Showing 1–50 of 137 filings
Key facts
CIK
1761612
CUSIP
088786108
13F (30d)
14 filings
14 filers
Visit website
Investor relations